Related Experiment Video

Updated: May 21, 2026

Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
12:45

Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer

Published on: February 12, 2022

The current state of targeted agents in rectal cancer

Dae Dong Kim1, Cathy Eng

  • 1Department of Surgery, Catholic University of Daegu, 3056-6 Daemyung-4 Dong, Nam-Gu, Daegu 705-718, Republic of Korea.

International Journal of Surgical Oncology
|June 8, 2012
PubMed

Insights

Targeted therapies have improved outcomes for metastatic colorectal cancer (CRC). Research explores their efficacy, toxicity, and personalized treatment potential, benefiting rectal cancer patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Targeted biologic agents are crucial in metastatic colorectal cancer (CRC) treatment, improving patient outcomes.
  • Advances in molecular diagnostics and gene sequencing drive personalized medicine in CRC.
  • Targeted therapies offer distinct mechanisms and toxicities compared to traditional chemotherapy.

Purpose of the Study:

  • To review a decade of clinical trials on targeted agents in locally advanced and metastatic CRC.
  • To assess the efficacy and toxicity of targeted therapies in CRC, including benefits for rectal cancer.
  • To explore the potential for personalized treatment regimens based on molecular markers.

Main Methods:

  • Review of clinical trials over the past decade focusing on targeted agents in CRC.
  • Analysis of efficacy and toxicity data from these trials.
  • Examination of the role of targeted therapies in rectal cancer treatment.

Main Results:

  • Targeted therapies have significantly improved outcomes in metastatic CRC.
  • Understanding of targeted agent mechanisms and toxicities has evolved.
  • Personalized treatment approaches are increasingly feasible.

Conclusions:

  • Targeted agents are integral to advanced CRC treatment, offering personalized options.
  • Further research is needed on novel agents targeting angiogenesis and signaling pathways.
  • Prospective studies in biomarker-defined subpopulations are essential for future advancements.

More Related Videos

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...